Cite
Berlin S, Goette A, Summo L, et al. Assessment of OMT-28, a synthetic analog of omega-3 epoxyeicosanoids, in patients with persistent atrial fibrillation: Rationale and design of the PROMISE-AF phase II study. Int J Cardiol Heart Vasc. 2020;29:100573doi: 10.1016/j.ijcha.2020.100573.
Berlin, S., Goette, A., Summo, L., Lossie, J., Gebauer, A., Al-Saady, N., Calo, L., Naccarelli, G., Schunck, W. H., Fischer, R., Camm, A. J., & Dobrev, D. (2020). Assessment of OMT-28, a synthetic analog of omega-3 epoxyeicosanoids, in patients with persistent atrial fibrillation: Rationale and design of the PROMISE-AF phase II study. International journal of cardiology. Heart & vasculature, 29100573. https://doi.org/10.1016/j.ijcha.2020.100573
Berlin, Sarah, et al. "Assessment of OMT-28, a synthetic analog of omega-3 epoxyeicosanoids, in patients with persistent atrial fibrillation: Rationale and design of the PROMISE-AF phase II study." International journal of cardiology. Heart & vasculature vol. 29 (2020): 100573. doi: https://doi.org/10.1016/j.ijcha.2020.100573
Berlin S, Goette A, Summo L, Lossie J, Gebauer A, Al-Saady N, Calo L, Naccarelli G, Schunck WH, Fischer R, Camm AJ, Dobrev D. Assessment of OMT-28, a synthetic analog of omega-3 epoxyeicosanoids, in patients with persistent atrial fibrillation: Rationale and design of the PROMISE-AF phase II study. Int J Cardiol Heart Vasc. 2020 Jul 10;29:100573. doi: 10.1016/j.ijcha.2020.100573. eCollection 2020 Aug. PMID: 32685659; PMCID: PMC7356118.
Copy
Download .nbib